GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Operating Margin %

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Operating Margin % : -2,833,750.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Chongqing Genrix Biopharmaceutical Co's Operating Income for the three months ended in Mar. 2024 was ¥-170.03 Mil. Chongqing Genrix Biopharmaceutical Co's Revenue for the three months ended in Mar. 2024 was ¥0.01 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2024 was -2,833,750.00%.

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's Operating Margin % or its related term are showing as below:

SHSE:688443' s Operating Margin % Range Over the Past 10 Years
Min: -446229.03   Med: -64900.25   Max: -749.7
Current: -68406.71


SHSE:688443's Operating Margin % is ranked worse than
97.24% of 1016 companies
in the Biotechnology industry
Industry Median: -154.335 vs SHSE:688443: -68406.71

Chongqing Genrix Biopharmaceutical Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Chongqing Genrix Biopharmaceutical Co's Operating Income for the three months ended in Mar. 2024 was ¥-170.03 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-764.10 Mil.

Warning Sign:

Chongqing Genrix Biopharmaceutical Co Ltd had lost money in 75% of the time over the past 12quarters.


Chongqing Genrix Biopharmaceutical Co Operating Margin % Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Operating Margin % Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
-446,229.03 -31,032.63 -749.70 -115,701.05 -64,900.25

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -192,513.00 -546,239.39 -3,032,283.33 -21,630.78 -2,833,750.00

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Operating Margin %

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Operating Margin % falls into.



Chongqing Genrix Biopharmaceutical Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Chongqing Genrix Biopharmaceutical Co's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-786.591 / 1.212
=-64,900.25 %

Chongqing Genrix Biopharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-170.025 / 0.006
=-2,833,750.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Chongqing Genrix Biopharmaceutical Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Headlines

No Headlines